HomeCompareHUMDF vs PLD

HUMDF vs PLD: Dividend Comparison 2026

HUMDF yields 484.14% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HUMDF wins by $47894.10M in total portfolio value
10 years
HUMDF
HUMDF
● Live price
484.14%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47900.01M
Annual income
$34,060,653,223.60
Full HUMDF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — HUMDF vs PLD

📍 HUMDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHUMDFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HUMDF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HUMDF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HUMDF
Annual income on $10K today (after 15% tax)
$41,152.26/yr
After 10yr DRIP, annual income (after tax)
$28,951,555,240.06/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, HUMDF beats the other by $28,947,517,123.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HUMDF + PLD for your $10,000?

HUMDF: 50%PLD: 50%
100% PLD50/50100% HUMDF
Portfolio after 10yr
$23952.96M
Annual income
$17,032,701,974.39/yr
Blended yield
71.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

HUMDF
No analyst data
Altman Z
3.9
Piotroski
5/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HUMDF buys
0
PLD buys
0
No recent congressional trades found for HUMDF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHUMDFPLD
Forward yield484.14%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$47900.01M$5.91M
Annual income after 10y$34,060,653,223.60$4,750,725.19
Total dividends collected$46687.76M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: HUMDF vs PLD ($10,000, DRIP)

YearHUMDF PortfolioHUMDF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$59,114$48,414.43$11,241$540.96+$47.9KHUMDF
2$330,728$267,475.81$13,019$991.13+$317.7KHUMDF
3$1,752,431$1,398,551.73$15,801$1,870.97+$1.74MHUMDF
4$8,800,812$6,925,711.29$20,609$3,701.21+$8.78MHUMDF
5$41,922,789$32,505,919.38$29,919$7,867.97+$41.89MHUMDF
6$189,569,894$144,712,509.91$50,631$18,617.74+$189.52MHUMDF
7$814,403,207$611,563,420.90$105,528$51,352.20+$814.30MHUMDF
8$3,326,842,984$2,455,431,552.18$287,364$174,449.42+$3326.56MHUMDF
9$12,933,979,587$9,374,257,594.32$1,081,760$774,280.77+$12932.90MHUMDF
10$47,900,011,382$34,060,653,223.60$5,908,209$4,750,725.19+$47894.10MHUMDF

HUMDF vs PLD: Complete Analysis 2026

HUMDFStock

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

Full HUMDF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this HUMDF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HUMDF vs SCHDHUMDF vs JEPIHUMDF vs OHUMDF vs KOHUMDF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.